Global Direct Oral Anticoagulants (DOACs) Market Growth 2026-2032
The global Direct Oral Anticoagulants (DOACs) market size is predicted to grow from US$ 49560 million in 2025 to US$ 85160 million in 2032; it is expected to grow at a CAGR of 8.2% from 2026 to 2032.
Direct oral anticoagulants (DOACs) are a class of medications used to prevent and treat blood clots by directly inhibiting specific enzymes involved in the clotting process.They include drugs that directly target either Factor Xa (such as rivaroxaban and apixaban) or thrombin (such as dabigatran), effectively reducing the risk of conditions like deep vein thrombosis, pulmonary embolism, and stroke in atrial fibrillation.
The market for Direct Oral Anticoagulants (DOACs) has experienced significant growth over the past decade. Initially introduced as alternatives to traditional anticoagulants like warfarin, DOACs offer advantages such as fixed dosing, fewer dietary restrictions, and minimal need for regular monitoring. The rising incidence of conditions such as atrial fibrillation and venous thromboembolism, coupled with an aging population, has driven increased demand for these medications. Consequently, the market has seen a surge in both prescription volume and the number of available DOACs.
In recent years, competition among pharmaceutical companies has intensified, leading to a broader range of DOAC options and potential price fluctuations. Major players like Bayer, Pfizer, and Bristol-Myers Squibb have continually advanced their products, seeking to differentiate through efficacy, safety profiles, and patient convenience. Additionally, the market has seen innovations such as the development of reversal agents for DOACs, addressing concerns over bleeding risks and enhancing the attractiveness of these drugs to both healthcare providers and patients.
Looking forward, the DOAC market is expected to continue its upward trajectory, driven by ongoing research, expanding indications, and increased global access. Emerging markets, where chronic diseases are rising alongside economic growth, present new opportunities for expansion. However, the market will also face challenges, including regulatory hurdles, potential generic competition, and the need for ongoing clinical trials to further establish long-term safety and efficacy. Overall, the DOAC market remains dynamic, with robust prospects shaped by evolving medical needs and technological advancements.
LP Information, Inc. (LPI) ' newest research report, the “Direct Oral Anticoagulants (DOACs) Industry Forecast” looks at past sales and reviews total world Direct Oral Anticoagulants (DOACs) sales in 2025, providing a comprehensive analysis by region and market sector of projected Direct Oral Anticoagulants (DOACs) sales for 2026 through 2032. With Direct Oral Anticoagulants (DOACs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Direct Oral Anticoagulants (DOACs) industry.
This Insight Report provides a comprehensive analysis of the global Direct Oral Anticoagulants (DOACs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Direct Oral Anticoagulants (DOACs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Direct Oral Anticoagulants (DOACs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Direct Oral Anticoagulants (DOACs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Direct Oral Anticoagulants (DOACs).
This report presents a comprehensive overview, market shares, and growth opportunities of Direct Oral Anticoagulants (DOACs) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Direct oral anticoagulants (DOACs) are a class of medications used to prevent and treat blood clots by directly inhibiting specific enzymes involved in the clotting process.They include drugs that directly target either Factor Xa (such as rivaroxaban and apixaban) or thrombin (such as dabigatran), effectively reducing the risk of conditions like deep vein thrombosis, pulmonary embolism, and stroke in atrial fibrillation.
The market for Direct Oral Anticoagulants (DOACs) has experienced significant growth over the past decade. Initially introduced as alternatives to traditional anticoagulants like warfarin, DOACs offer advantages such as fixed dosing, fewer dietary restrictions, and minimal need for regular monitoring. The rising incidence of conditions such as atrial fibrillation and venous thromboembolism, coupled with an aging population, has driven increased demand for these medications. Consequently, the market has seen a surge in both prescription volume and the number of available DOACs.
In recent years, competition among pharmaceutical companies has intensified, leading to a broader range of DOAC options and potential price fluctuations. Major players like Bayer, Pfizer, and Bristol-Myers Squibb have continually advanced their products, seeking to differentiate through efficacy, safety profiles, and patient convenience. Additionally, the market has seen innovations such as the development of reversal agents for DOACs, addressing concerns over bleeding risks and enhancing the attractiveness of these drugs to both healthcare providers and patients.
Looking forward, the DOAC market is expected to continue its upward trajectory, driven by ongoing research, expanding indications, and increased global access. Emerging markets, where chronic diseases are rising alongside economic growth, present new opportunities for expansion. However, the market will also face challenges, including regulatory hurdles, potential generic competition, and the need for ongoing clinical trials to further establish long-term safety and efficacy. Overall, the DOAC market remains dynamic, with robust prospects shaped by evolving medical needs and technological advancements.
LP Information, Inc. (LPI) ' newest research report, the “Direct Oral Anticoagulants (DOACs) Industry Forecast” looks at past sales and reviews total world Direct Oral Anticoagulants (DOACs) sales in 2025, providing a comprehensive analysis by region and market sector of projected Direct Oral Anticoagulants (DOACs) sales for 2026 through 2032. With Direct Oral Anticoagulants (DOACs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Direct Oral Anticoagulants (DOACs) industry.
This Insight Report provides a comprehensive analysis of the global Direct Oral Anticoagulants (DOACs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Direct Oral Anticoagulants (DOACs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Direct Oral Anticoagulants (DOACs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Direct Oral Anticoagulants (DOACs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Direct Oral Anticoagulants (DOACs).
This report presents a comprehensive overview, market shares, and growth opportunities of Direct Oral Anticoagulants (DOACs) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Oral Factor Xa Inhibitors
- Direct Thrombin Inhibitors (DTIs)
- Deep Vein Thrombosis
- Pulmonary Embolism
- Atrial Fibrillation
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bristol Myers Squibb
- Pfizer
- Daiichi Sankyo
- Janssen Pharmaceuticals
- Bayer
- Viatris
- Boehringer Ingelheim
- Accord Healthcare
- Sandoz
- Teva Pharmaceutical
- Mylan
- Apotex
- GlaxoSmithKline
- What is the 10-year outlook for the global Direct Oral Anticoagulants (DOACs) market?
- What factors are driving Direct Oral Anticoagulants (DOACs) market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Direct Oral Anticoagulants (DOACs) market opportunities vary by end market size?
- How does Direct Oral Anticoagulants (DOACs) break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Direct Oral Anticoagulants (DOACs) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Direct Oral Anticoagulants (DOACs) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Direct Oral Anticoagulants (DOACs) by Country/Region, 2021, 2025 & 2032
2.2 Direct Oral Anticoagulants (DOACs) Segment by Type
2.2.1 Oral Factor Xa Inhibitors
2.2.2 Direct Thrombin Inhibitors (DTIs)
2.2.3 Direct Oral Anticoagulants (DOACs) Sales by Type
2.2.3.1 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Direct Oral Anticoagulants (DOACs) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Direct Oral Anticoagulants (DOACs) Sale Price by Type (2021-2026)
2.3 Direct Oral Anticoagulants (DOACs) Segment by Application
2.3.1 Deep Vein Thrombosis
2.3.2 Pulmonary Embolism
2.3.3 Atrial Fibrillation
2.3.4 Other
2.3.5 Direct Oral Anticoagulants (DOACs) Sales by Application
2.3.5.1 Global Direct Oral Anticoagulants (DOACs) Sale Market Share by Application (2021-2026)
2.3.5.2 Global Direct Oral Anticoagulants (DOACs) Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Direct Oral Anticoagulants (DOACs) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Direct Oral Anticoagulants (DOACs) Breakdown Data by Company
3.1.1 Global Direct Oral Anticoagulants (DOACs) Annual Sales by Company (2021-2026)
3.1.2 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Company (2021-2026)
3.2 Global Direct Oral Anticoagulants (DOACs) Annual Revenue by Company (2021-2026)
3.2.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Company (2021-2026)
3.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Company (2021-2026)
3.3 Global Direct Oral Anticoagulants (DOACs) Sale Price by Company
3.4 Key Manufacturers Direct Oral Anticoagulants (DOACs) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Direct Oral Anticoagulants (DOACs) Product Location Distribution
3.4.2 Players Direct Oral Anticoagulants (DOACs) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DIRECT ORAL ANTICOAGULANTS (DOACS) BY GEOGRAPHIC REGION
4.1 World Historic Direct Oral Anticoagulants (DOACs) Market Size by Geographic Region (2021-2026)
4.1.1 Global Direct Oral Anticoagulants (DOACs) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Direct Oral Anticoagulants (DOACs) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Direct Oral Anticoagulants (DOACs) Market Size by Country/Region (2021-2026)
4.2.1 Global Direct Oral Anticoagulants (DOACs) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Direct Oral Anticoagulants (DOACs) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Direct Oral Anticoagulants (DOACs) Sales Growth
4.4 APAC Direct Oral Anticoagulants (DOACs) Sales Growth
4.5 Europe Direct Oral Anticoagulants (DOACs) Sales Growth
4.6 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Growth
5 AMERICAS
5.1 Americas Direct Oral Anticoagulants (DOACs) Sales by Country
5.1.1 Americas Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
5.1.2 Americas Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026)
5.2 Americas Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026)
5.3 Americas Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Direct Oral Anticoagulants (DOACs) Sales by Region
6.1.1 APAC Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026)
6.1.2 APAC Direct Oral Anticoagulants (DOACs) Revenue by Region (2021-2026)
6.2 APAC Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026)
6.3 APAC Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Direct Oral Anticoagulants (DOACs) by Country
7.1.1 Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
7.1.2 Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026)
7.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026)
7.3 Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Direct Oral Anticoagulants (DOACs) by Country
8.1.1 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026)
8.2 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026)
8.3 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Direct Oral Anticoagulants (DOACs)
10.3 Manufacturing Process Analysis of Direct Oral Anticoagulants (DOACs)
10.4 Industry Chain Structure of Direct Oral Anticoagulants (DOACs)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Direct Oral Anticoagulants (DOACs) Distributors
11.3 Direct Oral Anticoagulants (DOACs) Customer
12 WORLD FORECAST REVIEW FOR DIRECT ORAL ANTICOAGULANTS (DOACS) BY GEOGRAPHIC REGION
12.1 Global Direct Oral Anticoagulants (DOACs) Market Size Forecast by Region
12.1.1 Global Direct Oral Anticoagulants (DOACs) Forecast by Region (2027-2032)
12.1.2 Global Direct Oral Anticoagulants (DOACs) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Direct Oral Anticoagulants (DOACs) Forecast by Type (2027-2032)
12.7 Global Direct Oral Anticoagulants (DOACs) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Bristol Myers Squibb
13.1.1 Bristol Myers Squibb Company Information
13.1.2 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.1.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Bristol Myers Squibb Main Business Overview
13.1.5 Bristol Myers Squibb Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.2.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Daiichi Sankyo
13.3.1 Daiichi Sankyo Company Information
13.3.2 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.3.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Daiichi Sankyo Main Business Overview
13.3.5 Daiichi Sankyo Latest Developments
13.4 Janssen Pharmaceuticals
13.4.1 Janssen Pharmaceuticals Company Information
13.4.2 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.4.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Janssen Pharmaceuticals Main Business Overview
13.4.5 Janssen Pharmaceuticals Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.5.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Viatris
13.6.1 Viatris Company Information
13.6.2 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.6.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Viatris Main Business Overview
13.6.5 Viatris Latest Developments
13.7 Boehringer Ingelheim
13.7.1 Boehringer Ingelheim Company Information
13.7.2 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.7.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Boehringer Ingelheim Main Business Overview
13.7.5 Boehringer Ingelheim Latest Developments
13.8 Accord Healthcare
13.8.1 Accord Healthcare Company Information
13.8.2 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.8.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Accord Healthcare Main Business Overview
13.8.5 Accord Healthcare Latest Developments
13.9 Sandoz
13.9.1 Sandoz Company Information
13.9.2 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.9.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Sandoz Main Business Overview
13.9.5 Sandoz Latest Developments
13.10 Teva Pharmaceutical
13.10.1 Teva Pharmaceutical Company Information
13.10.2 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.10.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Teva Pharmaceutical Main Business Overview
13.10.5 Teva Pharmaceutical Latest Developments
13.11 Mylan
13.11.1 Mylan Company Information
13.11.2 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.11.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Mylan Main Business Overview
13.11.5 Mylan Latest Developments
13.12 Apotex
13.12.1 Apotex Company Information
13.12.2 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.12.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Apotex Main Business Overview
13.12.5 Apotex Latest Developments
13.13 GlaxoSmithKline
13.13.1 GlaxoSmithKline Company Information
13.13.2 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.13.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 GlaxoSmithKline Main Business Overview
13.13.5 GlaxoSmithKline Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Direct Oral Anticoagulants (DOACs) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Direct Oral Anticoagulants (DOACs) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Direct Oral Anticoagulants (DOACs) by Country/Region, 2021, 2025 & 2032
2.2 Direct Oral Anticoagulants (DOACs) Segment by Type
2.2.1 Oral Factor Xa Inhibitors
2.2.2 Direct Thrombin Inhibitors (DTIs)
2.2.3 Direct Oral Anticoagulants (DOACs) Sales by Type
2.2.3.1 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Direct Oral Anticoagulants (DOACs) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Direct Oral Anticoagulants (DOACs) Sale Price by Type (2021-2026)
2.3 Direct Oral Anticoagulants (DOACs) Segment by Application
2.3.1 Deep Vein Thrombosis
2.3.2 Pulmonary Embolism
2.3.3 Atrial Fibrillation
2.3.4 Other
2.3.5 Direct Oral Anticoagulants (DOACs) Sales by Application
2.3.5.1 Global Direct Oral Anticoagulants (DOACs) Sale Market Share by Application (2021-2026)
2.3.5.2 Global Direct Oral Anticoagulants (DOACs) Revenue and Market Share by Application (2021-2026)
2.3.5.3 Global Direct Oral Anticoagulants (DOACs) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Direct Oral Anticoagulants (DOACs) Breakdown Data by Company
3.1.1 Global Direct Oral Anticoagulants (DOACs) Annual Sales by Company (2021-2026)
3.1.2 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Company (2021-2026)
3.2 Global Direct Oral Anticoagulants (DOACs) Annual Revenue by Company (2021-2026)
3.2.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Company (2021-2026)
3.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Company (2021-2026)
3.3 Global Direct Oral Anticoagulants (DOACs) Sale Price by Company
3.4 Key Manufacturers Direct Oral Anticoagulants (DOACs) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Direct Oral Anticoagulants (DOACs) Product Location Distribution
3.4.2 Players Direct Oral Anticoagulants (DOACs) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR DIRECT ORAL ANTICOAGULANTS (DOACS) BY GEOGRAPHIC REGION
4.1 World Historic Direct Oral Anticoagulants (DOACs) Market Size by Geographic Region (2021-2026)
4.1.1 Global Direct Oral Anticoagulants (DOACs) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Direct Oral Anticoagulants (DOACs) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Direct Oral Anticoagulants (DOACs) Market Size by Country/Region (2021-2026)
4.2.1 Global Direct Oral Anticoagulants (DOACs) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Direct Oral Anticoagulants (DOACs) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Direct Oral Anticoagulants (DOACs) Sales Growth
4.4 APAC Direct Oral Anticoagulants (DOACs) Sales Growth
4.5 Europe Direct Oral Anticoagulants (DOACs) Sales Growth
4.6 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Growth
5 AMERICAS
5.1 Americas Direct Oral Anticoagulants (DOACs) Sales by Country
5.1.1 Americas Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
5.1.2 Americas Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026)
5.2 Americas Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026)
5.3 Americas Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Direct Oral Anticoagulants (DOACs) Sales by Region
6.1.1 APAC Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026)
6.1.2 APAC Direct Oral Anticoagulants (DOACs) Revenue by Region (2021-2026)
6.2 APAC Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026)
6.3 APAC Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Direct Oral Anticoagulants (DOACs) by Country
7.1.1 Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
7.1.2 Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026)
7.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026)
7.3 Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Direct Oral Anticoagulants (DOACs) by Country
8.1.1 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026)
8.2 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026)
8.3 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Direct Oral Anticoagulants (DOACs)
10.3 Manufacturing Process Analysis of Direct Oral Anticoagulants (DOACs)
10.4 Industry Chain Structure of Direct Oral Anticoagulants (DOACs)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Direct Oral Anticoagulants (DOACs) Distributors
11.3 Direct Oral Anticoagulants (DOACs) Customer
12 WORLD FORECAST REVIEW FOR DIRECT ORAL ANTICOAGULANTS (DOACS) BY GEOGRAPHIC REGION
12.1 Global Direct Oral Anticoagulants (DOACs) Market Size Forecast by Region
12.1.1 Global Direct Oral Anticoagulants (DOACs) Forecast by Region (2027-2032)
12.1.2 Global Direct Oral Anticoagulants (DOACs) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Direct Oral Anticoagulants (DOACs) Forecast by Type (2027-2032)
12.7 Global Direct Oral Anticoagulants (DOACs) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Bristol Myers Squibb
13.1.1 Bristol Myers Squibb Company Information
13.1.2 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.1.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Bristol Myers Squibb Main Business Overview
13.1.5 Bristol Myers Squibb Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.2.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 Daiichi Sankyo
13.3.1 Daiichi Sankyo Company Information
13.3.2 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.3.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Daiichi Sankyo Main Business Overview
13.3.5 Daiichi Sankyo Latest Developments
13.4 Janssen Pharmaceuticals
13.4.1 Janssen Pharmaceuticals Company Information
13.4.2 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.4.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Janssen Pharmaceuticals Main Business Overview
13.4.5 Janssen Pharmaceuticals Latest Developments
13.5 Bayer
13.5.1 Bayer Company Information
13.5.2 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.5.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Bayer Main Business Overview
13.5.5 Bayer Latest Developments
13.6 Viatris
13.6.1 Viatris Company Information
13.6.2 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.6.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Viatris Main Business Overview
13.6.5 Viatris Latest Developments
13.7 Boehringer Ingelheim
13.7.1 Boehringer Ingelheim Company Information
13.7.2 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.7.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Boehringer Ingelheim Main Business Overview
13.7.5 Boehringer Ingelheim Latest Developments
13.8 Accord Healthcare
13.8.1 Accord Healthcare Company Information
13.8.2 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.8.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Accord Healthcare Main Business Overview
13.8.5 Accord Healthcare Latest Developments
13.9 Sandoz
13.9.1 Sandoz Company Information
13.9.2 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.9.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Sandoz Main Business Overview
13.9.5 Sandoz Latest Developments
13.10 Teva Pharmaceutical
13.10.1 Teva Pharmaceutical Company Information
13.10.2 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.10.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Teva Pharmaceutical Main Business Overview
13.10.5 Teva Pharmaceutical Latest Developments
13.11 Mylan
13.11.1 Mylan Company Information
13.11.2 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.11.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Mylan Main Business Overview
13.11.5 Mylan Latest Developments
13.12 Apotex
13.12.1 Apotex Company Information
13.12.2 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.12.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Apotex Main Business Overview
13.12.5 Apotex Latest Developments
13.13 GlaxoSmithKline
13.13.1 GlaxoSmithKline Company Information
13.13.2 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
13.13.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 GlaxoSmithKline Main Business Overview
13.13.5 GlaxoSmithKline Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Direct Oral Anticoagulants (DOACs) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Direct Oral Anticoagulants (DOACs) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral Factor Xa Inhibitors
Table 4. Major Players of Direct Thrombin Inhibitors (DTIs)
Table 5. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 6. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Table 7. Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2026)
Table 9. Global Direct Oral Anticoagulants (DOACs) Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Direct Oral Anticoagulants (DOACs) Sale by Application (2021-2026) & (K Units)
Table 11. Global Direct Oral Anticoagulants (DOACs) Sale Market Share by Application (2021-2026)
Table 12. Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2026) & ($ million)
Table 13. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021-2026)
Table 14. Global Direct Oral Anticoagulants (DOACs) Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Direct Oral Anticoagulants (DOACs) Sales by Company (2021-2026) & (K Units)
Table 16. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Company (2021-2026)
Table 17. Global Direct Oral Anticoagulants (DOACs) Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Company (2021-2026)
Table 19. Global Direct Oral Anticoagulants (DOACs) Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Direct Oral Anticoagulants (DOACs) Producing Area Distribution and Sales Area
Table 21. Players Direct Oral Anticoagulants (DOACs) Products Offered
Table 22. Direct Oral Anticoagulants (DOACs) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Direct Oral Anticoagulants (DOACs) Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Direct Oral Anticoagulants (DOACs) Sales Market Share Geographic Region (2021-2026)
Table 27. Global Direct Oral Anticoagulants (DOACs) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Direct Oral Anticoagulants (DOACs) Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Country/Region (2021-2026)
Table 31. Global Direct Oral Anticoagulants (DOACs) Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units)
Table 34. Americas Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026)
Table 35. Americas Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 37. Americas Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units)
Table 38. APAC Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026) & (K Units)
Table 39. APAC Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2021-2026)
Table 40. APAC Direct Oral Anticoagulants (DOACs) Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 42. APAC Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units)
Table 43. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units)
Table 44. Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 46. Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Direct Oral Anticoagulants (DOACs)
Table 52. Key Market Challenges & Risks of Direct Oral Anticoagulants (DOACs)
Table 53. Key Industry Trends of Direct Oral Anticoagulants (DOACs)
Table 54. Direct Oral Anticoagulants (DOACs) Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Direct Oral Anticoagulants (DOACs) Distributors List
Table 57. Direct Oral Anticoagulants (DOACs) Customer List
Table 58. Global Direct Oral Anticoagulants (DOACs) Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Direct Oral Anticoagulants (DOACs) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Direct Oral Anticoagulants (DOACs) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Direct Oral Anticoagulants (DOACs) Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Direct Oral Anticoagulants (DOACs) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Direct Oral Anticoagulants (DOACs) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Direct Oral Anticoagulants (DOACs) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Direct Oral Anticoagulants (DOACs) Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Direct Oral Anticoagulants (DOACs) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Direct Oral Anticoagulants (DOACs) Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Direct Oral Anticoagulants (DOACs) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Bristol Myers Squibb Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 73. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 74. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Bristol Myers Squibb Main Business
Table 76. Bristol Myers Squibb Latest Developments
Table 77. Pfizer Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 78. Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 79. Pfizer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Pfizer Main Business
Table 81. Pfizer Latest Developments
Table 82. Daiichi Sankyo Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 83. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 84. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Daiichi Sankyo Main Business
Table 86. Daiichi Sankyo Latest Developments
Table 87. Janssen Pharmaceuticals Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 88. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 89. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Janssen Pharmaceuticals Main Business
Table 91. Janssen Pharmaceuticals Latest Developments
Table 92. Bayer Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 93. Bayer Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 94. Bayer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Bayer Main Business
Table 96. Bayer Latest Developments
Table 97. Viatris Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 98. Viatris Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 99. Viatris Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Viatris Main Business
Table 101. Viatris Latest Developments
Table 102. Boehringer Ingelheim Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 103. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 104. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Boehringer Ingelheim Main Business
Table 106. Boehringer Ingelheim Latest Developments
Table 107. Accord Healthcare Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 108. Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 109. Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Accord Healthcare Main Business
Table 111. Accord Healthcare Latest Developments
Table 112. Sandoz Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 113. Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 114. Sandoz Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Sandoz Main Business
Table 116. Sandoz Latest Developments
Table 117. Teva Pharmaceutical Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 118. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 119. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Teva Pharmaceutical Main Business
Table 121. Teva Pharmaceutical Latest Developments
Table 122. Mylan Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 123. Mylan Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 124. Mylan Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Mylan Main Business
Table 126. Mylan Latest Developments
Table 127. Apotex Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 128. Apotex Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 129. Apotex Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Apotex Main Business
Table 131. Apotex Latest Developments
Table 132. GlaxoSmithKline Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 133. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 134. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. GlaxoSmithKline Main Business
Table 136. GlaxoSmithKline Latest Developments
Table 1. Direct Oral Anticoagulants (DOACs) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Direct Oral Anticoagulants (DOACs) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral Factor Xa Inhibitors
Table 4. Major Players of Direct Thrombin Inhibitors (DTIs)
Table 5. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 6. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Table 7. Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2026)
Table 9. Global Direct Oral Anticoagulants (DOACs) Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Direct Oral Anticoagulants (DOACs) Sale by Application (2021-2026) & (K Units)
Table 11. Global Direct Oral Anticoagulants (DOACs) Sale Market Share by Application (2021-2026)
Table 12. Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021-2026) & ($ million)
Table 13. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021-2026)
Table 14. Global Direct Oral Anticoagulants (DOACs) Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Direct Oral Anticoagulants (DOACs) Sales by Company (2021-2026) & (K Units)
Table 16. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Company (2021-2026)
Table 17. Global Direct Oral Anticoagulants (DOACs) Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Company (2021-2026)
Table 19. Global Direct Oral Anticoagulants (DOACs) Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Direct Oral Anticoagulants (DOACs) Producing Area Distribution and Sales Area
Table 21. Players Direct Oral Anticoagulants (DOACs) Products Offered
Table 22. Direct Oral Anticoagulants (DOACs) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Direct Oral Anticoagulants (DOACs) Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Direct Oral Anticoagulants (DOACs) Sales Market Share Geographic Region (2021-2026)
Table 27. Global Direct Oral Anticoagulants (DOACs) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Direct Oral Anticoagulants (DOACs) Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Country/Region (2021-2026)
Table 31. Global Direct Oral Anticoagulants (DOACs) Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units)
Table 34. Americas Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026)
Table 35. Americas Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 37. Americas Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units)
Table 38. APAC Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026) & (K Units)
Table 39. APAC Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2021-2026)
Table 40. APAC Direct Oral Anticoagulants (DOACs) Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 42. APAC Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units)
Table 43. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units)
Table 44. Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 46. Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Direct Oral Anticoagulants (DOACs)
Table 52. Key Market Challenges & Risks of Direct Oral Anticoagulants (DOACs)
Table 53. Key Industry Trends of Direct Oral Anticoagulants (DOACs)
Table 54. Direct Oral Anticoagulants (DOACs) Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Direct Oral Anticoagulants (DOACs) Distributors List
Table 57. Direct Oral Anticoagulants (DOACs) Customer List
Table 58. Global Direct Oral Anticoagulants (DOACs) Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Direct Oral Anticoagulants (DOACs) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Direct Oral Anticoagulants (DOACs) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Direct Oral Anticoagulants (DOACs) Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Direct Oral Anticoagulants (DOACs) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Direct Oral Anticoagulants (DOACs) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Direct Oral Anticoagulants (DOACs) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Direct Oral Anticoagulants (DOACs) Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Direct Oral Anticoagulants (DOACs) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Direct Oral Anticoagulants (DOACs) Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Direct Oral Anticoagulants (DOACs) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Bristol Myers Squibb Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 73. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 74. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Bristol Myers Squibb Main Business
Table 76. Bristol Myers Squibb Latest Developments
Table 77. Pfizer Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 78. Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 79. Pfizer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Pfizer Main Business
Table 81. Pfizer Latest Developments
Table 82. Daiichi Sankyo Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 83. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 84. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Daiichi Sankyo Main Business
Table 86. Daiichi Sankyo Latest Developments
Table 87. Janssen Pharmaceuticals Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 88. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 89. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Janssen Pharmaceuticals Main Business
Table 91. Janssen Pharmaceuticals Latest Developments
Table 92. Bayer Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 93. Bayer Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 94. Bayer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. Bayer Main Business
Table 96. Bayer Latest Developments
Table 97. Viatris Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 98. Viatris Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 99. Viatris Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Viatris Main Business
Table 101. Viatris Latest Developments
Table 102. Boehringer Ingelheim Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 103. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 104. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 105. Boehringer Ingelheim Main Business
Table 106. Boehringer Ingelheim Latest Developments
Table 107. Accord Healthcare Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 108. Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 109. Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 110. Accord Healthcare Main Business
Table 111. Accord Healthcare Latest Developments
Table 112. Sandoz Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 113. Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 114. Sandoz Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 115. Sandoz Main Business
Table 116. Sandoz Latest Developments
Table 117. Teva Pharmaceutical Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 118. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 119. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 120. Teva Pharmaceutical Main Business
Table 121. Teva Pharmaceutical Latest Developments
Table 122. Mylan Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 123. Mylan Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 124. Mylan Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 125. Mylan Main Business
Table 126. Mylan Latest Developments
Table 127. Apotex Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 128. Apotex Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 129. Apotex Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 130. Apotex Main Business
Table 131. Apotex Latest Developments
Table 132. GlaxoSmithKline Basic Information, Direct Oral Anticoagulants (DOACs) Manufacturing Base, Sales Area and Its Competitors
Table 133. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolios and Specifications
Table 134. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 135. GlaxoSmithKline Main Business
Table 136. GlaxoSmithKline Latest Developments
LIST OF FIGURES
Figure 1. Picture of Direct Oral Anticoagulants (DOACs)
Figure 2. Direct Oral Anticoagulants (DOACs) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Direct Oral Anticoagulants (DOACs) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Direct Oral Anticoagulants (DOACs) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Direct Oral Anticoagulants (DOACs) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Direct Oral Anticoagulants (DOACs) Sales Market Share by Country/Region (2025)
Figure 10. Direct Oral Anticoagulants (DOACs) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral Factor Xa Inhibitors
Figure 12. Product Picture of Direct Thrombin Inhibitors (DTIs)
Figure 13. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type in 2026
Figure 14. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2026)
Figure 15. Direct Oral Anticoagulants (DOACs) Consumed in Deep Vein Thrombosis
Figure 16. Global Direct Oral Anticoagulants (DOACs) Market: Deep Vein Thrombosis (2021-2026) & (K Units)
Figure 17. Direct Oral Anticoagulants (DOACs) Consumed in Pulmonary Embolism
Figure 18. Global Direct Oral Anticoagulants (DOACs) Market: Pulmonary Embolism (2021-2026) & (K Units)
Figure 19. Direct Oral Anticoagulants (DOACs) Consumed in Atrial Fibrillation
Figure 20. Global Direct Oral Anticoagulants (DOACs) Market: Atrial Fibrillation (2021-2026) & (K Units)
Figure 21. Direct Oral Anticoagulants (DOACs) Consumed in Other
Figure 22. Global Direct Oral Anticoagulants (DOACs) Market: Other (2021-2026) & (K Units)
Figure 23. Global Direct Oral Anticoagulants (DOACs) Sale Market Share by Application (2025)
Figure 24. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application in 2026
Figure 25. Direct Oral Anticoagulants (DOACs) Sales by Company in 2026 (K Units)
Figure 26. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Company in 2026
Figure 27. Direct Oral Anticoagulants (DOACs) Revenue by Company in 2026 ($ millions)
Figure 28. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Company in 2026
Figure 29. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Direct Oral Anticoagulants (DOACs) Sales 2021-2026 (K Units)
Figure 32. Americas Direct Oral Anticoagulants (DOACs) Revenue 2021-2026 ($ millions)
Figure 33. APAC Direct Oral Anticoagulants (DOACs) Sales 2021-2026 (K Units)
Figure 34. APAC Direct Oral Anticoagulants (DOACs) Revenue 2021-2026 ($ millions)
Figure 35. Europe Direct Oral Anticoagulants (DOACs) Sales 2021-2026 (K Units)
Figure 36. Europe Direct Oral Anticoagulants (DOACs) Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Direct Oral Anticoagulants (DOACs) Revenue 2021-2026 ($ millions)
Figure 39. Americas Direct Oral Anticoagulants (DOACs) Sales Market Share by Country in 2026
Figure 40. Americas Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021-2026)
Figure 41. Americas Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Figure 42. Americas Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026)
Figure 43. United States Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Direct Oral Anticoagulants (DOACs) Sales Market Share by Region in 2026
Figure 48. APAC Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2021-2026)
Figure 49. APAC Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Figure 50. APAC Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026)
Figure 51. China Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 55. India Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Country in 2026
Figure 59. Europe Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021-2026)
Figure 60. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Figure 61. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026)
Figure 62. Germany Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 63. France Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026)
Figure 70. Egypt Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Direct Oral Anticoagulants (DOACs) in 2026
Figure 76. Manufacturing Process Analysis of Direct Oral Anticoagulants (DOACs)
Figure 77. Industry Chain Structure of Direct Oral Anticoagulants (DOACs)
Figure 78. Channels of Distribution
Figure 79. Global Direct Oral Anticoagulants (DOACs) Sales Market Forecast by Region (2027-2032)
Figure 80. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Direct Oral Anticoagulants (DOACs) Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Direct Oral Anticoagulants (DOACs) Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Direct Oral Anticoagulants (DOACs)
Figure 2. Direct Oral Anticoagulants (DOACs) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Direct Oral Anticoagulants (DOACs) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Direct Oral Anticoagulants (DOACs) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Direct Oral Anticoagulants (DOACs) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Direct Oral Anticoagulants (DOACs) Sales Market Share by Country/Region (2025)
Figure 10. Direct Oral Anticoagulants (DOACs) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral Factor Xa Inhibitors
Figure 12. Product Picture of Direct Thrombin Inhibitors (DTIs)
Figure 13. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type in 2026
Figure 14. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021-2026)
Figure 15. Direct Oral Anticoagulants (DOACs) Consumed in Deep Vein Thrombosis
Figure 16. Global Direct Oral Anticoagulants (DOACs) Market: Deep Vein Thrombosis (2021-2026) & (K Units)
Figure 17. Direct Oral Anticoagulants (DOACs) Consumed in Pulmonary Embolism
Figure 18. Global Direct Oral Anticoagulants (DOACs) Market: Pulmonary Embolism (2021-2026) & (K Units)
Figure 19. Direct Oral Anticoagulants (DOACs) Consumed in Atrial Fibrillation
Figure 20. Global Direct Oral Anticoagulants (DOACs) Market: Atrial Fibrillation (2021-2026) & (K Units)
Figure 21. Direct Oral Anticoagulants (DOACs) Consumed in Other
Figure 22. Global Direct Oral Anticoagulants (DOACs) Market: Other (2021-2026) & (K Units)
Figure 23. Global Direct Oral Anticoagulants (DOACs) Sale Market Share by Application (2025)
Figure 24. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application in 2026
Figure 25. Direct Oral Anticoagulants (DOACs) Sales by Company in 2026 (K Units)
Figure 26. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Company in 2026
Figure 27. Direct Oral Anticoagulants (DOACs) Revenue by Company in 2026 ($ millions)
Figure 28. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Company in 2026
Figure 29. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Direct Oral Anticoagulants (DOACs) Sales 2021-2026 (K Units)
Figure 32. Americas Direct Oral Anticoagulants (DOACs) Revenue 2021-2026 ($ millions)
Figure 33. APAC Direct Oral Anticoagulants (DOACs) Sales 2021-2026 (K Units)
Figure 34. APAC Direct Oral Anticoagulants (DOACs) Revenue 2021-2026 ($ millions)
Figure 35. Europe Direct Oral Anticoagulants (DOACs) Sales 2021-2026 (K Units)
Figure 36. Europe Direct Oral Anticoagulants (DOACs) Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Direct Oral Anticoagulants (DOACs) Revenue 2021-2026 ($ millions)
Figure 39. Americas Direct Oral Anticoagulants (DOACs) Sales Market Share by Country in 2026
Figure 40. Americas Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021-2026)
Figure 41. Americas Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Figure 42. Americas Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026)
Figure 43. United States Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Direct Oral Anticoagulants (DOACs) Sales Market Share by Region in 2026
Figure 48. APAC Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2021-2026)
Figure 49. APAC Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Figure 50. APAC Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026)
Figure 51. China Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 55. India Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Country in 2026
Figure 59. Europe Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021-2026)
Figure 60. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Figure 61. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026)
Figure 62. Germany Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 63. France Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021-2026)
Figure 70. Egypt Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Direct Oral Anticoagulants (DOACs) Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Direct Oral Anticoagulants (DOACs) in 2026
Figure 76. Manufacturing Process Analysis of Direct Oral Anticoagulants (DOACs)
Figure 77. Industry Chain Structure of Direct Oral Anticoagulants (DOACs)
Figure 78. Channels of Distribution
Figure 79. Global Direct Oral Anticoagulants (DOACs) Sales Market Forecast by Region (2027-2032)
Figure 80. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Direct Oral Anticoagulants (DOACs) Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Direct Oral Anticoagulants (DOACs) Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share Forecast by Application (2027-2032)
